text
"['\n3. 원재료 및 생산설비\n1) 주요 원재료 등의 현황\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0(단위 : 천원 %)\r\n사업부문\n매입유형\n품 \xa0 목\n구체적용도\n매입액\n비율\n비 고\n의약품\n원재료\nBERAPROST SODIUM\n베리실정\n\xa0911,876\n13.64\nCRUDE-MEROPENEM\n메로페넴\n\xa0520,083\n10.86\nCEFMETAZOLE FREE ACID\n세프메타졸\n\xa0903,000\n9.14\nLANSOPRAZOLE PELLETS(IRELAND)\n란스톤캡슐\n\xa0613,860\n9.06\nEPINASTINE.HBr\xa0\n에피나스틴\n\xa01,360,800\n6.16\nTIANEPTINE SOD\n스타브론정\n\xa0503,380\n5.21\n티에스원 캡슐 20 1 C\n티에스원 캡슐\n\xa0342,449\n5.04\nCRUDE MEROPENEM kg\n메로페넴\n\xa01,082,896\n4.71\nCEFOTETAN(국제)\n야마테탄\n\xa0 \xa0 \xa0 \xa0470,195\n3.43\n기타\n\xa03,266,930\n32.75\n합계\n9,975,469\n100\n부재료\nROSUVASTATIN PMBt-BUTYL ESTER\n로스바스틴\n\xa0 \xa0 \xa0 \xa0140,156\n9.20\nCHITOSAN\n무코스타 서방정\n\xa0 \xa0 \xa0 \xa0139,500\n9.16\nNAI(SODIUM IODIDE)\n세프디토렌\n\xa0 \xa0 \xa0 \xa0132,408\n8.69\nAMINO METHACRYLATE COPOLYMER(EUDRAGIT EPO)\n무코스타 서방정\n\xa0 \xa0 \xa0 \xa0 87,400\n5.74\nSODIUM CARBONATE ANHYDROUS(NF)\n무코스타 서방정\n\xa0 \xa0 \xa0 \xa0 85,000\n5.58\nE.A(CF)\n에피나스틴 외\n\xa0 \xa0 \xa0 \xa0 64,260\n4.22\n기타\n\xa0 \xa0 \xa0 \xa0874,520\n57.41\n합계\n1,523,244\n100\n포장재료\nACLAR FILM(0.329*232mm)(200m)\n니코챔스 정외\n\xa0 \xa0 \xa0 \xa0277,071\n28.53\n테프론 고무마개(W2T32-B1-S)\n크라비트 주외\n\xa0 \xa0 \xa0 \xa0 84,672\n8.72\n무색 VIAL(φ30,60mm)\n뉴로페넴 주외\n\xa0 \xa0 \xa0 \xa0 75,218\n7.75\n공용용기(80mL)\n안프란 정외\n\xa0 \xa0 \xa0 \xa0 25,200\n2.59\n기타\n\u3000\n\xa0 \xa0 \xa0 \xa0509,142\n52.41\n합계\n\u3000\n971,303\n100\n총 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0계\n12,470,016\n2) 주요 원재료 등의 가격변동추이\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 (단위: 원)\n품 \xa0목\n제6기 1분기\n제5기\n제4기\nEPINASTINE.HBr\xa0\n1,200,000\n1,100,000\n1,100,000\nLANSOPRAZOLE PELLETS\n935,762\n918,771\n957,023\nBERAPROST SODIUM\n5,281,900\n5,621,729\n6,273,078\nROSUVASTATIN CALCIUM\n2,500,000\n2,478,125\n2,500,000\nROSUVASTATIN PMB t-BUTYL ESTER\n1,430,160\n1,377,243\n1,438,476\n테프론 고무마개(W2T32-B1-S)\n420\n420\n420\n(1)산출기준 : 평균구입가격 표시(2)주요가격변동 원인 : 환율변동 및 원료비 단가변동\n3) 생산 및 설비에 관한 사항\n가. 생산능력 및 생산능력의 산출근거\n(1) 생산능력\n품 \xa0목\n단위\n구 분 /\xa0\n규 격\n2022년(제6기 1분기)\n2021년(제5기)\n2020년(제4기)\n정제\n정\n36\n47,692,800\n\xa0 \xa0190,771,200\n\xa0 \xa0190,771,200\n36\n71,539,200\n\xa0 \xa0286,156,800\n\xa0 \xa0286,156,800\n32\n33,177,600\n\xa0 \xa0132,710,400\n\xa0 \xa0132,710,400\n39\n95,472,000\n\xa0 \xa0381,888,000\n\xa0 \xa0381,888,000\n캡슐제\n정\n36\n37,324,800\n\xa0 \xa0149,299,200\n\xa0 \xa0149,299,200\n34\n33,292,800\n\xa0 \xa0133,171,200\n\xa0 \xa0133,171,200\n56\n90,316,800\n\xa0 \xa0361,267,200\n\xa0 \xa0361,267,200\n주사제\n바이알\n-\n288,000\n\xa0 \xa0 \xa0 1,152,000\n\xa0 \xa0 \xa0 1,152,000\n합성원료\nkg\n라인1\n1,500\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 6,000\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 6,000\n라인2\n225\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0900\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0900\n세파일반\n1,000\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 4,000\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 4,000\n세파무균\n2,500\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa010,000\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa010,000\n페넴무균\n3,500\n\xa0 \xa0 \xa0 \xa0 \xa0 14,000\n\xa0 \xa0 \xa0 \xa0 \xa0 14,000\n(2) 산출기준 및 산출방법 등\n(2)-1 산출기준\n주요 생산 설비의 기본수용력을 기준으로 작성되었습니다.\xa0\n구 \xa0분\n(단위)\n규격(발수)\n최대속도\n(RPM)\n표준속도\n(RPM)\n시간당 최대\n시간당 표준\n연간최대\n연간표준\n정제\n(정)\n36\xa0\n70\xa0\n46\xa0\n151,200\xa0\n99,360\xa0\n290,304,000\xa0\n190,771,200\xa0\n36\xa0\n70\xa0\n69\xa0\n151,200\xa0\n149,040\xa0\n290,304,000\xa0\n286,156,800\xa0\n32\xa0\n50\xa0\n36\xa0\n96,000\xa0\n69,120\xa0\n184,320,000\xa0\n132,710,400\xa0\n39\xa0\n90\xa0\n85\xa0\n210,600\xa0\n198,900\xa0\n404,352,000\xa0\n381,888,000\xa0\n캡슐제\n(정)\n36\xa0\n50\xa0\n36\xa0\n108,000\xa0\n77,760\xa0\n207,360,000\xa0\n149,299,200\xa0\n34\xa0\n52\xa0\n34\xa0\n106,080\xa0\n69,360\xa0\n203,673,600\xa0\n133,171,200\xa0\n56\xa0\n125\xa0\n56\xa0\n420,000\xa0\n188,160\xa0\n806,400,000\xa0\n361,267,200\xa0\n주사제\n(바이알)\n1일4시간1주4일 가동\n1,200\xa0\n1,200\xa0\n1,200\xa0\n1,200\xa0\n2,304,000\xa0\n1,152,000\xa0\n품목\n구분\n산출량\n연간사이클수\n연속\n연간최대\n합성원료(kg)\n라인1\n50\n120\n1\n6,000\n라인2\n2.5\n120\n3\n900\n세파일반\n40\n50\n2\n4,000\n세파무균\n100\n50\n2\n10,000\n페넴무균\n140\n50\n2\n14,000\n합 \xa0 \xa0 \xa0계\n34,900\n(2)-2 산출방법\n품 \xa0목\n산 출 방 법\n정제, 캡슐제\n연간표준 = 규격발수 X 표준속도 X 8시간 X 240일\n주사제\n연간표준 = 시간당 표준 \xa0X 4시간 X 240일\n합성원료\n연간최대 = 산출량 X 연간사이클수 X \xa0연속수\n평균가동일수*8시간(일일작업시간)*시간당 생산능력(3) 평균가동시간\n일평균 가동시간 : 8시간 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0월평균 가동시간 : 20일(160시간)연평균가동시간 \xa0: 240일(1,920시간)\n나. 생산실적 및 가동률\n(1) 생산실적\n(단위 : 천원 )\n사업부문\n품목\n사업소\n제6기 1분기\n제5기\n제4기\n의약품제 \xa0 조\n베라실 정\n445,546\n4,261,065\n4,970,389\n티에스원캅셀\n876,758\n2,928,924\n3,790,071\n란스톤캅셀\n1,062,986\n3,861,156\n3,896,692\n야마테탄 주\n764,767\n1,508,588\n2,927,043\n스타브론 정\n515,450\n3,166,217\n3,491,033\n옴니세프\xa0\n746,428\n1,359,910\n853,020\n크라비트주\n791,606\n2,405,291\n2,982,467\n넥실렌정\n451,165\n3,205,996\n3,944,080\n가스트렉스 과립\n524,042\n1,591,808\n1,768,139\n론서프정\n0\n1,863,298\n1,369,427\n리피토플러스\n334,060\n2,050,237\n0\n기타\n15,801,091\n53,263,457\n60,735,680\n합 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 계\n22,313,899\n81,465,947\n90,728,041\n(2) 당해 사업연도의 가동률\n(단위 : 시간)\n사업소(사업부문)\n가동가능시간\n실제가동시간\n평균가동률\n의약품제조\n480\n261\n54.38\n합 계\n480\n261\n54.38\n다. 생산설비의 현황 등\n제일약품(주) 2022년 1분기 생산설비의 변동내역은 다음과 같습니다.\n(1) 생산설비의 현황\n(단위 : ㎡,천원 )\n자산항목\n소유형태\n소재지\n기초장부가액\n당기증감\n당기상각\n기말장부가액\n비고\n증가\n감소\n토지\n자가\n용인\n27,148,806\n-\n27,148,806\n-\n건물\n자가\n용인\n64,674,863\n-\n467,658\n64,207,205\n-\n구축물\n자가\n용인\n24,780\n-\n16,298\n8,482\n-\n기계장치\n자가\n용인\n5,806,666\n706,300\n3\n546,674\n5,966,289\n-\n차량운반구\n자가\n용인\n13,808\n-\n2,764\n11,044\n-\n공구기구\n자가\n용인\n1,023,515\n60,098\n2\n131,696\n951,915\n-\n집기비품\n자가\n용인\n474,734\n40,303\n40,075\n474,962\n-\n시설물\n자가\n용인\n5,914,363\n-\n265,085\n5,649,278\n-\n합계\n105,081,535\n806,701\n5\n1,470,250\n104,417,981\n-\n(2) 설비의 신설ㆍ매입 계획 등\n\xa0 \xa0 \xa0설비의 신설 및 매입계획이 없습니다.\n']"
